Sahla Waqas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sahla Waqas has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Usman Iqbal
Department of Medicine, King Edward Medical University, Lahore, Pakistan
2 shared publications - Abdel Rahman Feras AlSamhori
University of Jordan, Amman, Jordan
1 shared publication - Alina Jamshed
Department of Medicine, CMH Multan Institute of Medical Sciences, Multan, Pakistan
1 shared publication - Anjal Shah
B.P. Koirala Institute of Health Sciences
1 shared publication - Arbab Khalid
Kirk Kerkorian School of Medicine at UNLV, Las Vegas, USA
1 shared publication - Areesha Wasti
Continental Medical College, Lahore, Pakistan
1 shared publication
Latest Publications
- 12 October 2026
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 13 (1) , 17
Prevalence and Antimicrobial Resistance of Klebsiella pneumoniae in Pakistan, 2015–2025: A Systematic Review and Meta-Analysis
- 12 October 2026
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 13 (1) , 17
Prevalence and Antimicrobial Resistance of Klebsiella pneumoniae in Pakistan, 2015–2025: A Systematic Review and Meta-Analysis
- Open Access
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- 3 October 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
Pharmacological Innovations in Managing Cancer Therapy Related Skin Toxicities: A Narrative Review for Supportive Oncology
Introduction: Cutaneous toxicities are common and distressing complications of cancer therapy, impairing quality of life (QoL), treatment adherence, and psychological well-being. Despite their high prevalence, management has historically relied on supportive measures with limited efficacy. Recognizing skin health as integral to supportive oncology, this review highlights novel pharmacological strategies that may improve outcomes and reduce treatment interruptions. Areas covered: We conducted a literature search (PubMed, Embase, Cochrane; 2015–2025) to synthesize evidence on skin toxicities across chemotherapy, targeted therapies, immunotherapy, and radiotherapy. We discuss pathophysiological mechanisms underlying these toxicities and emerging pharmacological interventions, including biologics (dupilumab, JAK inhibitors), barrier-repair agents, antioxidants, advanced topical and systemic formulations, and repurposed drugs. Special attention is given to vulnerable populations—patients with darker skin phototypes, those in low- and middle-income countries (LMICs), and pediatric/geriatric oncology patients—where equity gaps in evidence and access are most pressing. Expert opinion: Dermatologic adverse events are no longer secondary concerns; they represent a central component of supportive oncology. Innovative, mechanism-based pharmacological approaches hold promise to transform management, but robust randomized controlled trials remain limited. Future directions include biomarker-driven prevention, integration of digital toxicity monitoring, and global equity–focused guidelines. Prioritizing dermatologic health alongside oncologic efficacy can help preserve treatment intensity, minimize hospitalizations, and enhance patient quality of life worldwide
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessPharmacological Innovations in Managing Cancer Therapy Related Skin Toxicities: A Narrative Review for Supportive Oncology
Introduction: Cutaneous toxicities are common and distressing complications of cancer therapy, impairing quality of life (QoL), treatment adherence, and psychological well-being. Despite their high prevalence, management has historically relied on supportive measures with limited efficacy. Recognizing skin health as integral to supportive oncology, this review highlights novel pharmacological strategies that may improve outcomes and reduce treatment interruptions. Areas covered: We conducted a literature search (PubMed, Embase, Cochrane; 2015–2025) to synthesize evidence on skin toxicities across chemotherapy, targeted therapies, immunotherapy, and radiotherapy. We discuss pathophysiological mechanisms underlying these toxicities and emerging pharmacological interventions, including biologics (dupilumab, JAK inhibitors), barrier-repair agents, antioxidants, advanced topical and systemic formulations, and repurposed drugs. Special attention is given to vulnerable populations—patients with darker skin phototypes, those in low- and middle-income countries (LMICs), and pediatric/geriatric oncology patients—where equity gaps in evidence and access are most pressing. Expert opinion: Dermatologic adverse events are no longer secondary concerns; they represent a central component of supportive oncology. Innovative, mechanism-based pharmacological approaches hold promise to transform management, but robust randomized controlled trials remain limited. Future directions include biomarker-driven prevention, integration of digital toxicity monitoring, and global equity–focused guidelines. Prioritizing dermatologic health alongside oncologic efficacy can help preserve treatment intensity, minimize hospitalizations, and enhance patient quality of life worldwide